Delpazolid - LegoChem Biosciences

Drug Profile

Delpazolid - LegoChem Biosciences

Alternative Names: LCB-01371; RMX 2001

Latest Information Update: 27 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LegoChem Biosciences
  • Class Antibacterials; Oxazolidinones; Small molecules; Triazines
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Tuberculosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Tuberculosis
  • Phase I Methicillin-resistant Staphylococcus aureus infections; Vancomycin-resistant enterococcal infections

Most Recent Events

  • 24 Jul 2018 China National Drug Administration approves IND application for delpazolid in Tuberculosis
  • 24 Jul 2018 Delpazolid receives fast track designation for Tuberculosis in USA prior to July 2018
  • 24 Jul 2018 LegoChem Biosciences plans a phase IIb trial for Tuberculosis in USA and China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top